A Global Platform for Innovative Research in Life Sciences

Isabella Rose Bennett
Institute of Cancer Research and Nanotherapeutics, Imperial College London, London, UK

* Corresponding Author: **Isabella Rose Bennett**

Article Info

E-ISSN: 3107-7137
Volume: 02
Issue: 02
Received: 05-12-2025
Accepted: 03-02-2026
Published: 01-03-2026
Page No: 01-06

Abstract

Background: The life sciences are undergoing a paradigm shift, driven by the convergence of digital technologies, multi-omics data, and artificial intelligence. This transformation necessitates a global, integrated platform to accelerate discovery, translate findings into clinical applications, and address complex health challenges that transcend national borders.

Recent Advances: Significant progress has been made in establishing the foundations for such a platform. Advances include the development of secure, cloud-based research environments such as Terra, which enable collaborative analysis of genomic and clinical data across institutions. International consortia and open science initiatives are promoting data sharing and interoperability. Key technological drivers—including next-generation sequencing, CRISPR-based genome engineering, and AI-powered predictive modelling—are maturing rapidly and becoming accessible on a global scale.

Key Challenges: Despite these advances, substantial barriers remain. These include fragmentation of funding for essential biodata infrastructure, lack of interoperability between disparate data systems, disparities in research capacity between high-income and low- and middle-income countries, and complex ethical and regulatory considerations surrounding data privacy, gene editing, and equitable access to innovation.

Future Directions: The next decade will witness the convergence of biology with engineering and computational sciences. Priorities include establishing sustainable funding models for global biodata resources, developing federated data infrastructures that respect national sovereignty while enabling collaboration, strengthening biosecurity and pandemic preparedness, and fostering public–private partnerships that align commercial incentives with public health goals. A coordinated global platform offers the strategic potential to democratise life sciences research and accelerate solutions for sustainable development and health equity.

Keywords: Global research platform; life sciences; open science; artificial intelligence; precision medicine; data governance; research infrastructure

1. Introduction

The life sciences encompass the systematic study of living organisms, from molecular mechanisms to ecosystem dynamics, and form the foundation for advances in medicine, agriculture, biotechnology, and environmental sustainability. The scope of modern life sciences research extends from genomic sequencing and synthetic biology to population health and personalised therapeutics, reflecting an increasingly interdisciplinary endeavour that integrates biology with chemistry, physics, engineering, and computational science [1].

The evolution of global research collaboration in the life sciences has accelerated markedly over the past two decades. The Human Genome Project, completed in 2003, exemplified the power of international cooperation and set a precedent for large-scale, data-intensive biology. Subsequent initiatives—including the International HapMap Project, the Cancer Genome Atlas, and more recently global efforts to characterise the human microbiome and map the human brain—have demonstrated that the

most ambitious scientific questions require coordinated action across institutions, sectors, and national boundaries [2].

The COVID-19 pandemic provided both a stress test and a catalyst for global research collaboration. The rapid sharing of pathogen genomic sequences, the acceleration of vaccine development through platforms such as mRNA technology, and the establishment of distributed clinical trial networks illustrated what becomes possible when barriers to data sharing and collaboration are temporarily lowered [3]. However, the pandemic also exposed persistent vulnerabilities: fragmented data systems, inequitable access to diagnostics and therapeutics, and the fragility of funding models for essential research infrastructure [4].

These observations point to a compelling need: the establishment of a sustained, integrated global platform for life sciences research. Such a platform would not be a single physical entity but rather a coordinated ecosystem of digital infrastructures, governance frameworks, and collaborative practices that enables researchers worldwide to access data, share tools, and accelerate discovery. This review examines the foundations, technological drivers, translational pathways, and governance considerations for such a platform, with the aim of providing a comprehensive overview of the opportunities and challenges inherent in building a truly global approach to life sciences innovation.

2. Foundations of a Global Research Platform in Life Sciences

The construction of a global research platform rests upon several interdependent foundations: digital research ecosystems, open science practices, international consortia, and robust bioinformatics infrastructure. These elements collectively enable the seamless integration of data, tools, and expertise across geographical and institutional boundaries.

Digital research ecosystems have emerged as critical infrastructure for contemporary life sciences. Platforms such as Terra, co-developed by the Broad Institute, Microsoft, and Verily, provide secure, scalable environments where researchers can access data, run analytical workflows, and collaborate across institutions [5]. A recent collaboration between M42, the Broad Institute, Microsoft, and the International Center for Genetic Disease illustrates the potential of such platforms to support national precision medicine programmes while contributing diverse genomic datasets to global research [6]. Terra, deployed on cloud infrastructure with sovereign capabilities, serves both as a trusted research environment for data security and as a foundation for omics-powered clinical trials [6].

Open science and data-sharing initiatives constitute a second essential foundation. The Barcelona Declaration on Open Research Information represents an international commitment to making research outputs—including data, software, and methods—openly available and reusable by default [7]. The World Data System's endorsement of this declaration reflects growing recognition that transparency and accessibility are prerequisites for accelerating discovery [7]. Similarly, the Global Biodata Coalition has articulated principles for cooperative funding models to sustain essential biodata resources, emphasising collective responsibility among research funders and adherence to FAIR (Findable, Accessible, Interoperable, Reusable) principles [8].

International research consortia provide the organisational frameworks within which collaboration occurs. The recently launched International Health Data Space Initiative (IHDSI) brings together institutions from Luxembourg, the United States, and South Korea to establish federated infrastructure for privacy-compliant health data integration, with initial focus on precision oncology and complex diseases [9]. Such initiatives demonstrate how sovereign data spaces can be interconnected to enable multi-institutional research while respecting national regulatory frameworks.

Cloud computing and bioinformatics infrastructure underpin the technical capabilities required for modern life sciences research. The partnership between the Broad Institute and Manifold to develop an AI-enabled research platform illustrates the trajectory of infrastructure development, incorporating capabilities such as ‘bring your own cloud’ support, purpose-built AI agents for natural language querying, and enhanced scalability to accommodate exponentially growing biomedical datasets [10]. Table 1 summarises the core components of a global life sciences research platform.

Table 1: Core Components of a Global Life Sciences Research Platform

Component	Description	Key Technologies	Impact on Research
Digital Research Environments	Secure, cloud-based platforms for data access and analysis	Terra, Microsoft Azure, trusted research environments	Enables secure collaboration across institutions; supports scalable analysis
Open Science Infrastructure	Systems and policies for open data sharing	FAIR principles, Barcelona Declaration, biodata repositories	Accelerates discovery through data reuse; enhances reproducibility
International Consortia	Organisational frameworks for multi-national collaboration	IHDSI, Global Biodata Coalition, distributed governance models	Facilitates large-scale studies; pools expertise and resources
Cloud Computing	Scalable computational infrastructure	Hybrid cloud, federated data connectors, AI-optimised platforms	Accommodates exponential data growth; democratises access to advanced analytics

3. Technological Drivers of Innovation

The vision of a global research platform is made feasible by rapid advances in foundational technologies. These technologies not only generate the data that flow through the platform but also provide the analytical and experimental capabilities that enable new forms of discovery.

Genomics and next-generation sequencing have undergone extraordinary progress since the completion of the Human Genome Project. The cost of sequencing a human genome has fallen from approximately $100 million in 2001 to less than $1,000 today, making population-scale genomic studies feasible in diverse settings [11]. Third-generation sequencing technologies now enable the detection of structural variants and epigenetic modifications that were previously inaccessible, providing a more complete view of genomic variation [12].

Multi-omics integration extends beyond genomics to encompass transcriptomics, proteomics, metabolomics, and epigenomics. The challenge lies not merely in generating these data types but in integrating them to reveal biological mechanisms. Recent frameworks, such as the bio-digital feedback loop proposed for precision mushroom breeding,

illustrate how multi-omics data can be used to decipher gene networks governing complex traits, from substrate degradation enzymes to secondary metabolite pathways [13]. Such integrative approaches are applicable across domains, from crop improvement to human disease research.

Artificial intelligence and machine learning have become indispensable tools for biological discovery. AlphaFold's demonstration of accurate protein structure prediction based on amino acid sequences represented a transformative moment, solving a fifty-year challenge in biology and opening new avenues for drug discovery and protein engineering [14]. AI applications now extend to image analysis in pathology and radiology, natural language processing of scientific literature, and predictive modelling of drug-target interactions. The integration of AI agents directly into research platforms—enabling capabilities such as automated cohort building and gene expression analysis—promises to democratise access to advanced analytical methods [10].

CRISPR and genome engineering technologies have revolutionised the ability to manipulate DNA with precision. CRISPR-Cas9 and its derivatives enable gene knockout, knock-in, and base editing across diverse organisms, from microbes to humans. The combination of CRISPR with synthetic biology approaches allows the design of modular gene circuits and 'plug-and-play' chassis strains for biotechnology applications [13]. In clinical contexts, CRISPR-based therapies are advancing through clinical trials for genetic disorders including sickle cell disease and beta-thalassaemia.

Synthetic biology and biofoundries represent the industrialisation of biological design. Biofoundries combine automation, standardised genetic parts, and design–build–test–learn cycles to accelerate the engineering of biological systems. These facilities are increasingly connected through global networks, enabling distributed design and local manufacturing of biologics, diagnostics, and sustainable materials. Table 2 summarises the enabling technologies transforming life sciences research.

Table 2: Enabling Technologies Transforming Life Sciences Research

Technology	Principle	Major Applications	Current Limitations
Next-Generation Sequencing	High-throughput parallel sequencing of DNA	Population genomics, rare disease diagnosis, pathogen surveillance	Data storage and analysis bottlenecks; interpretation of variants
Multi-Omics Integration	Combined analysis of genomic, transcriptomic, proteomic, and metabolomic data	Biomarker discovery, systems biology, precision medicine	Computational complexity; lack of standardised integration methods
Artificial Intelligence	Machine learning models trained on biological data	Protein structure prediction, drug discovery, image analysis	'Black box' interpretability; dependence on training data quality
CRISPR Genome Engineering	RNA-guided nucleases for precise DNA modification	Gene therapy, crop improvement, functional genomics	Off-target effects; delivery challenges in vivo
Synthetic Biology	Design and construction of new biological systems	Engineered cell factories, biosensors, living therapeutics	Complexity of biological systems; biocontainment concerns

4. Translational and Clinical Integration

The ultimate purpose of a global research platform is to accelerate the translation of fundamental discoveries into clinical applications that improve human health. This translational pathway encompasses multiple stages, from early biomarker discovery through to global clinical trials and real-world evidence generation.

Precision medicine and personalised therapeutics represent the clinical manifestation of insights derived from genomics and multi-omics. The Emirati Genome Programme, having completed more than 500,000 whole genome sequences, illustrates how national initiatives can generate population-specific genomic data that inform both disease prevention and therapeutic development [6]. Such programmes are most valuable when their data can be integrated with global datasets, enabling the discovery of variants that are rare in some populations but more common in others.

Global clinical trial networks are essential infrastructure for evaluating new interventions across diverse populations. The COVID-19 pandemic demonstrated both the potential and the limitations of existing trial networks. While platform trials such as RECOVERY and SOLIDARITY generated practice-changing evidence rapidly, disparities in trial site locations meant that populations in low- and middle-income countries were often underrepresented in clinical development [15]. Emerging initiatives seek to address these imbalances through distributed trial designs and capacity building in underrepresented regions [16].

Biomarker discovery and validation benefit substantially from the scale and diversity that a global platform enables. The International Health Data Space Initiative's focus on bladder cancer and Parkinson's disease cohorts exemplifies how federated infrastructure can support the identification of molecular markers that guide diagnosis and treatment selection [9]. By enabling analysis across multiple cohorts while maintaining data sovereignty, such approaches address both scientific and regulatory requirements.

Real-world data and digital health platforms are increasingly recognised as complements to traditional clinical trials. Electronic health records, wearable device data, and patient-reported outcomes provide evidence on how interventions perform in routine clinical practice. The integration of real-world data with genomic and clinical trial data within secure research environments creates opportunities for pharmacovigilance, comparative effectiveness research, and the refinement of treatment guidelines. Table 3 outlines the translational pathways within a global research framework.

Table 3: Translational Pathways within a Global Research Framework

Research Stage	Description	Challenges	Regulatory Considerations
Discovery Research	Identification of disease mechanisms and therapeutic targets	Reproducibility; validation across model systems	Basic research oversight; intellectual property management
Biomarker Development	Identification and validation of molecular markers for diagnosis or prognosis	Sample size requirements; population specificity	Clinical validity requirements; laboratory accreditation
Preclinical Development	*In vitro* and animal studies to establish safety and efficacy	Translational relevance; species differences	Good Laboratory Practice; animal welfare standards
Clinical Trials	Human studies to establish safety and efficacy	Patient recruitment; diversity of participants	Good Clinical Practice; ethics committee approval; regulatory authority oversight
Real-World Evidence	Post-approval studies using routine clinical data	Data quality; confounding	Privacy regulations; secondary use consent frameworks

5. Governance, Ethics, and Equity in Global Research

The technical capabilities of a global research platform must be matched by robust governance frameworks that address ethical considerations, protect participant privacy, and ensure equitable access to the benefits of innovation.

Ethical considerations in gene editing and AI require particular attention as these technologies mature. Genome editing in human embryos remains controversial, with international consensus yet to emerge on acceptable boundaries. The development of heritable genetic modifications raises profound ethical questions about intergenerational consent and the potential for eugenic applications [17]. Similarly, AI applications in healthcare raise concerns about algorithmic bias, transparency, and the appropriate role of automated decision-making in clinical contexts. Ensuring that AI systems are trained on diverse datasets is essential to prevent the perpetuation of existing health disparities [18].

Data governance and privacy regulations vary significantly across jurisdictions, creating challenges for international data sharing. The European Union's General Data Protection Regulation (GDPR) establishes stringent requirements for processing personal data, including health information, and has become a reference point for privacy regulation globally [19]. The International Health Data Space Initiative explicitly aligns with the European Health Data Space (EHDS) framework and GAIA-X protocols, demonstrating how federated architectures can accommodate regulatory diversity while enabling collaborative research [9]. Key to this approach is the principle of data sovereignty: data remain under the control of their originating institutions, with only analytical queries and aggregated results shared across borders.

Intellectual property management in a global research platform requires balancing incentives for innovation with the imperative for broad access. The COVID-19 pandemic reignited debates about patent monopolies, technology transfer, and voluntary licensing arrangements. Initiatives such as the Medicines Patent Pool demonstrate how voluntary licensing can expand access to patented technologies in low- and middle-income countries while maintaining commercial incentives in high-income markets [20]. Emerging models, including open-source biotechnology and prize-based incentives, offer alternatives to traditional intellectual property frameworks.

Equity in global access to innovation remains a persistent challenge. The concentration of research and development capacity in high-income countries means that the health priorities of low- and middle-income populations are often underfunded [21]. The 90:10 Institute and the Kavli Center for Ethics, Science, and the Public have collaborated to reimagine biotechnology development pathways that better align commercial translation with public health needs [22]. Such efforts recognise that expanding the range of viable pathways from discovery to accessible interventions is essential if science is to serve society equitably.

Capacity building in low- and middle-income countries is both an ethical imperative and a practical necessity for global research. Diverse datasets require diverse research communities capable of generating, analysing, and interpreting data from their own populations. The World Data System's membership includes institutions from South Africa, Canada, Japan, and Australia, reflecting a commitment to building data management capacity across regions [7]. Training programmes in data curation, bioinformatics, and research ethics are essential components of a sustainable global platform. Table 4 summarises key policy and governance frameworks.

Table 4: Global Policy and Governance Frameworks in Life Sciences Research

Framework/Initiative	Region/Scope	Focus Area	Implementation Challenges
General Data Protection Regulation (GDPR)	European Union	Data privacy and protection	Compliance complexity; tension with open data principles
European Health Data Space (EHDS)	European Union	Health data exchange and secondary use	Interoperability standards; cross-border governance
FAIR Principles	Global	Data findability, accessibility, interoperability, reusability	Adoption across disciplines; measurement of compliance
Barcelona Declaration	Global	Open research information	Transition from subscription-based models; sustainability
Global Biodata Coalition	Global	Sustainable funding for biodata resources	Coordination among diverse funders; priority setting
Nagoya Protocol	Global	Access to genetic resources and benefit-sharing	Implementation complexity; impediment to non-commercial research

6. Challenges to Building a Sustainable Global Platform

Despite the compelling vision and substantial progress, significant challenges must be addressed to realise a sustainable global platform for life sciences research.

Funding disparities represent perhaps the most fundamental obstacle. Research and development investment remains heavily concentrated in high-income countries, with low- and middle-income countries accounting for a small fraction of global health research spending [21]. This concentration affects not only the generation of data but also the capacity to participate in data analysis and interpretation. The Global Biodata Coalition's White Paper highlights the precarious funding situation for essential biodata resources, noting that fragmented and uncoordinated support threatens the long-term viability of infrastructure upon which the entire research enterprise depends [8].

Infrastructure gaps extend beyond funding to encompass physical and technical resources. High-performance computing, reliable internet connectivity, and secure data storage cannot be taken for granted in all research settings. Cloud-based approaches offer potential solutions by shifting infrastructure requirements from institutions to providers, but they also introduce dependencies on commercial vendors and require reliable network access.

Interoperability of data systems remains a persistent technical challenge. Despite widespread endorsement of FAIR principles, actual implementation varies considerably across disciplines, institutions, and jurisdictions. Differences in data models, terminology systems, and consent frameworks impede the integration of datasets from multiple sources. The development and adoption of community standards—such as those promoted by the Global Alliance for Genomics and Health—are essential but proceed slowly [23].

Political and regulatory fragmentation creates barriers to international collaboration. National approaches to data protection, export controls, and research oversight reflect different cultural values and policy priorities. While federated architectures can accommodate some diversity, they add complexity and may limit the types of analyses that can be performed across borders. The absence of international agreements on issues such as genome editing governance leaves researchers navigating uncertain and potentially conflicting guidance.

Biosecurity concerns have intensified as biotechnology becomes more powerful and accessible. The same technologies that enable rapid vaccine development—synthetic biology, genome editing, AI-assisted design—could potentially be misused to create novel pathogens or enhance the virulence of existing ones [24]. Balancing openness and collaboration with responsible oversight requires careful attention to dual-use research of concern and the development of governance mechanisms that do not unduly impede beneficial research.

7. Future Perspectives

Looking forward, several converging trends will shape the evolution of global life sciences research platforms over the next decade.

The convergence of biology, engineering, and computational sciences will accelerate, blurring traditional disciplinary boundaries. The bio-digital feedback loop concept, which integrates multi-omics data, CRISPR engineering, and AI-driven phenomics, exemplifies the integrated approach that will become increasingly prevalent [13]. Such convergence enables iterative cycles of design, build, test, and learn that compress development timelines and enable the engineering of biological systems with unprecedented precision.

Global pandemic preparedness has risen on the policy agenda following COVID-19, creating opportunities for sustained investment in surveillance and response infrastructure. AI-based epidemic prediction, next-generation sequencing for pathogen surveillance, and CRISPR-based diagnostics offer the potential for near-real-time threat detection and characterisation [24]. The challenge lies in maintaining readiness during inter-pandemic periods and ensuring that investments benefit routine public health functions as well as emergency response.

Sustainable biotechnology represents a growing priority as concerns about climate change, resource depletion, and biodiversity loss intensify. Biological solutions to industrial processes—from bioplastics and biofuelsto sustainable agriculture—offer pathways to reduce environmental impact. Global research platforms can accelerate the development of these solutions by enabling the sharing of genetic parts, strains, and fermentation data across distributed biofoundries [25].

The role of public–private partnerships will be central to platform sustainability. Neither public funding alone nor commercial models can adequately support the full spectrum of research infrastructure. The collaboration between M42, the Broad Institute, and Microsoft illustrates a hybrid model in which public research institutions, private healthcare providers, and technology companies contribute complementary capabilities [6]. The challenge is to structure such partnerships such that public interests—including open data, equitable access, and long-term sustainability—are protected alongside commercial returns.

The vision for the next decade is one in which researchers anywhere in the world can contribute to and benefit from a global knowledge commons. A researcher in South Africa studying genomic variants associated with tuberculosis susceptibility should be able to compare findings with datasets from Asia and Europe, using analytical tools developed in Brazil or India, within a secure environment that respects participant privacy and data sovereignty. Achieving this vision requires sustained commitment to the principles of openness, interoperability, and equity that underpin the scientific enterprise.

8. Conclusion

This review has examined the foundations, technological drivers, translational pathways, and governance considerations for a global platform for innovative research in life sciences. The core argument is that the accelerating pace of biological discovery, combined with the maturation of digital infrastructure, creates both the necessity and the opportunity for sustained global collaboration.

The key themes that emerge from this analysis include the centrality of digital research environments as the infrastructure within which collaboration occurs; the enabling role of technologies such as genomics, AI, and genome engineering; the importance of governance frameworks that address ethics, privacy, and equity; and the persistent challenges of funding disparities, infrastructure gaps, and regulatory fragmentation.

The strategic importance of coordinated global platforms cannot be overstated. The grand challenges of the twenty-first century—emerging infectious diseases, the burden of non-

communicable conditions, environmental degradation, and food insecurity—all have biological dimensions that require scientific solutions. No single institution, and no single nation, possesses the full range of capabilities needed to address these challenges alone. Collective action, enabled by shared infrastructure and sustained by mutual trust, is essential.

The outlook for advancing innovation in life sciences is ultimately optimistic. The technical capabilities at our disposal are unprecedented. The commitment of researchers, funders, and policymakers to open science and global collaboration has been demonstrated repeatedly, most recently in the response to the COVID-19 pandemic. The task ahead is to build on these foundations, learning from both successes and failures, to construct platforms that serve science and society for generations to come.

8. References

1. National Academies of Sciences, Engineering, and Medicine. *The future of life sciences research*. Washington (DC): The National Academies Press; 2021.
2. Green ED, Gunter C, Biesecker LG, *et al*. Strategic vision for improving human health at the forefront of genomics. Nature. 2020;586(7831):683-692.
3. Maxmen A. One year on: how the COVID pandemic unfolded. Nature. 2021;589(7842):342-345.
4. Sachs JD, Karim SSA, Aknin L, *et al*. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet. 2022;400(10359):1224-1280.
5. Broad Institute. Terra: a scalable platform for biomedical research. 2023. Available from: https://terra.bio
6. M42. M42 and Broad Institute work together with Microsoft and the International Center for Genetic Disease leveraging Terra to enable a foundation for precision health. 2026 Feb 9. Available from: https://m42.ae/media-resources/news/m42-and-broad-institute-work-together-with-microsoft-and-the-international-center-for-genetic-disease-leveraging-terra-to-enable-a-foundation-for-precision-health/
7. World Data System. WDS endorses the Barcelona Declaration on Open Research Information. 2025 Jul 17. Available from: https://icsu-wds.org/
8. Global Biodata Coalition. Working cooperatively for global biodata resource sustainability: a white paper. 2025 Jan. Available from: https://globalbiodata.org/white-paper-published/
9. Luxembourg Institute of Health. Global partnership launches International Health Data Space Initiative (IHDSI) to accelerate AI-driven precision medicine and cancer research. 2025 Jul 22. Available from: https://www.lih.lu/en/article/global-partnership-launches-international-health-data-space-initiative-ihdsi-to-accelerate-ai-driven-precision-medicine-and-cancer-research/
10. Select Science. Broad Institute and Manifold collaborate to build AI-enabled life sciences research platform to accelerate global discoveries. 2025 Jan 27. Available from: https://www.selectscience.net/article/broad-institute-and-manifold-collaborate-to-build-ai-enabled-life-sciences-research-platform-to
11. National Human Genome Research Institute. DNA sequencing costs: data. 2023. Available from: https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data
12. Athanasopoulou K, Boti MA, Adamopoulos PG, Skourou PC, Scorilas A. Third-generation sequencing: the spearhead towards the radical transformation of modern genomics. Life (Basel). 2021;12(1):30.
13. Das A, Sharma V, Kumar A, Singh S. Bio-digital feedback loop systems: a synergistic integration of predictive genomics, genome editing, and AI-driven phenomic synthesis for next-generation edible and medicinal mushroom breeding. Antonie Van Leeuwenhoek. 2025;118(11):168.
14. Jumper J, Evans R, Pritzel A, *et al*. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589.
15. Miller JE, Millum J. Ethical considerations in international clinical trial site selection. BMJ Glob Health. 2022;7: e008012.
16. Varma T, Jones CP, Oladele C, Miller J. Diversity in clinical research: public health and social justice imperatives. J Med Ethics. 2022; 49:200-203.
17. National Academy of Medicine, National Academy of Sciences, Royal Society. *Heritable human genome editing*. Washington (DC): The National Academies Press; 2020.
18. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
19. European Parliament and Council of the European Union. General Data Protection Regulation (GDPR). Off J Eur Union. 2016; L119:1-88.
20. Medicines Patent Pool. *Annual report 2023*. Geneva: MPP; 2024.
21. Global Forum for Health Research. *Monitoring financial flows for health research*. Geneva: Global Forum for Health Research; 2022.
22. Kavli Center for Ethics, Science, and the Public. The Kavli Center partnered with the 90:10 Institute to reimagine biotech for society. 2025 Sep 1. Available from: https://kavlicenter.berkeley.edu/news/kavli-center-partnered-9010-institute-reimagine-biotech-society
23. Rehm HL, Page AJH, Smith L, *et al*. GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics. 2021;1(2):100029.
24. Okon MB, Adebayo A, Okon IE, *et al*. From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats. Front Public Health. 2025; 13:1711344.
25. French KE. Harnessing synthetic biology for sustainable development. Nat Sustain. 2019; 2:250-257.

How to Cite This Article

Bennett IR. A global platform for innovative research in life sciences. International Journal of Biological and Biomedical Research. 2026;2(2):1–6.